Home  /  Resource Library  /  BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL-LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL)

BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL-LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL)

Retrospective study examined brentuximab vedotin following autologous stem cell transplant for treatment of relapsed hodgkin lymphoma.